(ECL) Ecolab - NYSE
Sector: Basic Materials | Industry: Specialty Chemicals | Exchange: NYSE (USA) | Market Cap: 74.696m USD | Total Return: 4.1% in 12m
Avg Turnover: 471M
EPS Trend: 98.2%
Qual. Beats: 0
Rev. Trend: 94.0%
Qual. Beats: 3
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Ecolab Inc. (NYSE: ECL) is a U.S.-based provider of water, hygiene, and infection prevention solutions and services, operating both domestically and internationally. Founded in 1923 and headquartered in Saint Paul, Minnesota, the company is classified within the GICS Materials sector under the Specialty Chemicals sub-industry. As a specialty chemicals producer, Ecolab typically generates revenue through formulation and service-based contracts rather than commodity chemical sales.
The company operates through four reportable segments: Global Water, Global Institutional & Specialty, Global Pest Elimination, and Global Life Sciences. The Global Water segment supplies water treatment, process applications, and cleaning and sanitizing solutions to heavy industries including manufacturing, food and beverage processing, energy, refining, petrochemical, and pulp and paper. The Global Institutional & Specialty segment serves foodservice, healthcare, hospitality, lodging, government, education, and retail customers with cleaning and sanitizing products. Ecolabs business model is largely B2B, relying on a mix of direct field sales, corporate account personnel, distributors, and dealers.
The Global Pest Elimination segment provides pest detection, prevention, and extermination services targeting restaurants, food processors, hotels, grocery operations, and other commercial facilities, while the Global Life Sciences segment delivers cleaning and contamination control solutions to pharmaceutical and personal care manufacturers. Ecolab sells its offerings under several brand names, including Ecolab, Kay, Purolite, and Bioquell. The company has been publicly traded since its 1988 IPO.
- Industrial water demand rises with U.S. manufacturing activity
- Foodservice and hospitality volumes drive Institutional segment growth
- Raw material cost inflation pressures gross margins
| Net Income: 2.11b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA 0.75 > 1.0 |
| NWC/Revenue: -0.32% < 20% (prev 9.38%; Δ -9.71% < -1%) |
| CFO/TA 0.12 > 3% & CFO 3.03b > Net Income 2.11b |
| Net Debt (9.52b) to EBITDA (3.88b): 2.45 < 3 |
| Current Ratio: 0.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (283.7m) vs 12m ago -0.56% < -2% |
| Gross Margin: 44.29% > 18% (prev 43.71%; Δ 0.58% > 0.5%) |
| Asset Turnover: 69.41% > 50% (prev 70.13%; Δ -0.72% > 0%) |
| Interest Coverage Ratio: 9.41 > 6 (EBIT TTM 2.88b / Interest Expense TTM 306.0m) |
| A: -0.00 (Total Current Assets 6.04b - Total Current Liabilities 6.10b) / Total Assets 25.0b |
| B: 0.52 (Retained Earnings 13.1b / Total Assets 25.0b) |
| C: 0.12 (EBIT TTM 2.88b / Avg Total Assets 23.7b) |
| D: 0.67 (Book Value of Equity 10.0b / Total Liabilities 15.0b) |
| Altman-Z'' = 3.20 = A |
| DSRI: 1.15 (Receivables 3.64b/3.02b, Revenue 16.5b/15.7b) |
| GMI: 0.99 (GM 43.71% / 44.29%) |
| AQI: 1.05 (AQ_t 0.55 / AQ_t-1 0.53) |
| SGI: 1.05 (Revenue 16.5b / 15.7b) |
| TATA: -0.04 (NI 2.11b - CFO 3.03b) / TA 25.0b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of June 21, 2026, the stock is trading at USD 269.12 with a total of 3,332,636 shares traded.
Over the past week, the price has changed by +2.36%,
over one month by +9.82%,
over three months by +4.31% and
over the past year by +4.12%.
Ecolab has received a consensus analysts rating of 4.19. Therefore, it is recommended to buy ECL.
- StrongBuy: 13
- Buy: 6
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 317.1 | 17.8% |
P/E Trailing = 35.9634
P/E Forward = 31.6456
P/S = 4.5402
P/B = 7.4667
P/EG = 2.4566
Revenue TTM = 16.5b USD
EBIT TTM = 2.88b USD
EBITDA TTM = 3.88b USD
Long Term Debt = 6.92b USD (from longTermDebt, last quarter)
Short Term Debt = 1.74b USD (from shortTermDebt, last quarter)
Debt = 10.0b USD (from shortLongTermDebtTotal, last quarter) + Leases 770.8m
Net Debt = 9.52b USD (calculated: Debt 10.0b - CCE 519.8m)
Enterprise Value = 84.2b USD (74.7b + Debt 10.0b - CCE 519.8m)
Interest Coverage Ratio = 9.41 (Ebit TTM 2.88b / Interest Expense TTM 306.0m)
EV/FCF = 45.03x (Enterprise Value 84.2b / FCF TTM 1.87b)
FCF Yield = 2.22% (FCF TTM 1.87b / Enterprise Value 84.2b)
FCF Margin = 11.37% (FCF TTM 1.87b / Revenue TTM 16.5b)
Net Margin = 12.80% (Net Income TTM 2.11b / Revenue TTM 16.5b)
Gross Margin = 44.29% ((Revenue TTM 16.5b - Cost of Revenue TTM 9.17b) / Revenue TTM)
Gross Margin QoQ = 43.55% (prev 44.03%)
Tobins Q-Ratio = 3.36 (Enterprise Value 84.2b / Total Assets 25.0b)
Interest Expense / Debt = 3.05% (Interest Expense 306.0m / Debt 10.0b)
Taxrate = 18.20% (472.6m / 2.60b)
NOPAT = 2.35b (EBIT 2.88b * (1 - 18.20%))
Current Ratio = 0.99 (Total Current Assets 6.04b / Total Current Liabilities 6.10b)
Debt / Equity = 1.00 (Debt 10.0b / totalStockholderEquity, last quarter 10.0b)
Debt / EBITDA = 2.45 (Net Debt 9.52b / EBITDA 3.88b)
Debt / FCF = 5.09 (Net Debt 9.52b / FCF TTM 1.87b)
Total Stockholder Equity = 9.70b (last 4 quarters mean from totalStockholderEquity)
RoA = 8.88% (Net Income 2.11b / Total Assets 25.0b)
RoE = 21.70% (Net Income TTM 2.11b / Total Stockholder Equity 9.70b)
RoCE = 17.31% (EBIT 2.88b / Capital Employed (Equity 9.70b + L.T.Debt 6.92b))
RoIC = 11.67% (NOPAT 2.35b / Invested Capital 20.2b)
WACC = 6.87% (E(74.7b)/V(84.7b) * Re(7.46%) + D(10.0b)/V(84.7b) * Rd(3.05%) * (1-Tc(0.18)))
Discount Rate = 7.46% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.40 | Cagr: -0.53%
[DCF] Terminal Value 77.97% ; FCFF base≈1.72b ; Y1≈1.98b ; Y5≈2.91b
[DCF] Fair Price = 121.6 (EV 43.8b - Net Debt 9.52b = Equity 34.2b / Shares 281.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 98.20 | EPS CAGR: 20.13% | SUE: 0.0 | # QB: 0
Revenue Correlation: 94.01 | Revenue CAGR: 3.02% | SUE: 1.30 | # QB: 3
EPS current Quarter (2026-06-30): EPS=2.07 | Chg30d=+0.08% | Revisions=+25% | Analysts=19
EPS next Quarter (2026-09-30): EPS=2.27 | Chg30d=-0.29% | Revisions=+14% | Analysts=15
EPS current Year (2026-12-31): EPS=8.38 | Chg30d=-0.32% | Revisions=-11% | GrowthEPS=+11.3% | GrowthRev=+10.1%
EPS next Year (2027-12-31): EPS=9.60 | Chg30d=-0.14% | Revisions=+25% | GrowthEPS=+14.6% | GrowthRev=+6.4%
[Analyst] Revisions Ratio: +25%